This article is freely available to all

Article Abstract

Despite methodological flaws that limit conclusions, a considerable database documents the efficacyof triiodothyronine (T3) as an augmentation strategy for response to various classes of antidepressants.One study suggests that T3 and lithium are of comparable efficacy in antidepressantnonresponders. No clear biochemical or clinical predictors of preferential response to T3 have beenfound. The role of T3 augmentation requires further evaluation, especially with regard to dose andduration